<DOC>
	<DOC>NCT02810457</DOC>
	<brief_summary>The purpose of this research study is to compare the effectiveness and safety of FKB238 against AvastinÂ® in men and women with advanced/recurrent non squamous non-small cell lung cancer</brief_summary>
	<brief_title>Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients aged 18 years or older Newly diagnosed advanced (stage IV) /recurrent nonsquamous NSCLC for which they had not received any systemic anticancer therapy for metastatic disease Histologically or cytologically confirmed diagnosis of predominantly nonsquamous NSCLC Existence of at least 1 measurable lesion by RECIST v1.1 Adequate hematological, renal and liver function Eastern Collaborative Oncology Group Performance Status (ECOG PS) 0 or 1 Life expectancy longer than 6 months Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamouscell tumors and mixed adenosquamous carcinomas of predominantly squamous nature Any unresolved toxicities from prior systemic therapy Known sensitizing EGFR mutations or EML4ALK translocation positive mutations Previous dosing with vascular endothelial growth factor (VEGF) inhibitor Known hypersensitivity to any excipients of the Investigational Products (IPs) and combination chemotherapy Use of prohibited concomitant medication Known Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection Fertile men or women of childbearing potential not using adequate contraception. Other inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>